Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,307.01 -14.40 (-0.27%) Dow
39,671.04 -201.95 (-0.51%) Nasdaq
16,801.54 -31.08 (-0.18%) Bitcoin USD
69,747.02 -400.52 (-0.57%) CMC Crypto 200
1,501.92 -0.74 (-0.05%)
PFE Jul 2024 16.000 put
- Barrons.com
CDC Confirms a Second Bird Flu Case in U.S. Dairy Worker. Vaccine Momentum Builds.
U.S. officials said Wednesday that a Michigan dairy worker had tested positive for avian influenza, the second known human case in the U.S. since the virus was detected in late March in cattle. The Centers for Disease Control and Prevention said that the patient only had eye symptoms, similar to the first known infected dairy worker, who developed conjunctivitis in Texas in March. The CDC said that it still considers the risk from the current outbreak to the general public to be low.
- Reuters
Pfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027
Investors have fled from Pfizer as pandemic worries declined and billions of dollars in COVID-19 vaccine and treatment sales disappeared. Pfizer's shares were up 2.6% at $29.30 in afternoon trading. Pfizer made the disclosure on Wednesday in a filing with the Securities and Exchange Commission.
- Benzinga
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid
